dalteparin has been researched along with Aging in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset." | 5.14 | Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009) |
| " The present study investigates if the physiological deterioration of renal function associated with normal aging or the presence of an acute venous thromboembolism influences the pharmacodynamic pattern of the anti-factor Xa and anti-thrombin activities." | 2.69 | Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). ( Boneu, B; d'Azemar, P; Decousus, H; Duret, JP; Gaud, C; Laporte-Simitsidis, S; Mismetti, P; Navarro, C; Necciari, J; Sié, P, 1998) |
| " Compared with unfractionated heparin (UFH), nadroparin has a greater ratio of anti-factor Xa to anti-factor Ha activity, greater bioavailability and a longer duration of action, allowing it to be administered by subcutaneous injection for prophylaxis or treatment of thromboembolic disorders." | 2.40 | Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. ( Davis, R; Faulds, D, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, X | 1 |
| Liang, J | 1 |
| Li, X | 1 |
| Hu, Z | 1 |
| Chen, J | 1 |
| Zheng, J | 1 |
| Li, R | 1 |
| Davis, R | 1 |
| Faulds, D | 1 |
| Mismetti, P | 1 |
| Laporte-Simitsidis, S | 1 |
| Navarro, C | 1 |
| Sié, P | 1 |
| d'Azemar, P | 1 |
| Necciari, J | 1 |
| Duret, JP | 1 |
| Gaud, C | 1 |
| Decousus, H | 1 |
| Boneu, B | 1 |
| Krantz, EN | 1 |
| Philpott, CD | 1 |
| Droege, ME | 1 |
| Mueller, EW | 1 |
| Ernst, NE | 1 |
| Garber, PM | 1 |
| Tsuei, BJ | 1 |
| Goodman, MD | 1 |
| Droege, CA | 1 |
| Lopes, RD | 1 |
| Alexander, KP | 1 |
| Manoukian, SV | 1 |
| Bertrand, ME | 1 |
| Feit, F | 1 |
| White, HD | 1 |
| Pollack, CV | 1 |
| Hoekstra, J | 1 |
| Gersh, BJ | 1 |
| Stone, GW | 1 |
| Ohman, EM | 1 |
| Georgescu, A | 1 |
| Alexandru, N | 1 |
| Nemecz, M | 1 |
| Titorencu, I | 1 |
| Popov, D | 1 |
| Ignjatovic, V | 1 |
| Mertyn, E | 1 |
| Monagle, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Aging
| Article | Year |
|---|---|
Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Topics: Absorption; Aging; Anticoagulants; Chemical Fractionation; Cost-Benefit Analysis; Dose-Response Rela | 1997 |
The coagulation system in children: developmental and pathophysiological considerations.
Topics: Adult; Aging; Anticoagulants; Antithrombin III; Blood Coagulation; Child; Child Development; Enoxapa | 2011 |
2 trials available for dalteparin and Aging
| Article | Year |
|---|---|
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Topics: Adult; Aged; Aging; Anticoagulants; Creatinine; Factor Xa Inhibitors; Female; Humans; Injections, Su | 1998 |
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter | 2009 |
3 other studies available for dalteparin and Aging
| Article | Year |
|---|---|
Identify Key Genes Correlated to Ischemia-Reperfusion Injury in Aging Livers.
Topics: Aging; Animals; ARNTL Transcription Factors; Humans; Immediate-Early Proteins; Liver; Mice; Nadropar | 2023 |
Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Enoxaparin; Female; Humans; Incidence; | 2020 |
Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway.
Topics: Adrenergic Agents; Aging; Animals; Arterioles; Cricetinae; Diabetes Mellitus, Experimental; Diabetes | 2011 |